Volume 9, Issue 4 (12-2021)                   JoMMID 2021, 9(4): 221-224 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Gyandev Gondode P, Garg A, Sahoo S, Sharma A. The quandary over Antiviral Therapy for a COVID-19 Patient with Glucose-6-Phosphate Dehydrogenase Deficiency, Hypertension, and Resolved Hepatitis B Infection: A Case Report. JoMMID 2021; 9 (4) :221-224
URL: http://jommid.pasteur.ac.ir/article-1-368-en.html
The quandary over Antiviral Therapy for a COVID-19 Patient with Glucose-6-Phosphate Dehydrogenase Deficiency, Hypertension, and Resolved Hepatitis B Infection: A Case Report
Prakash Gyandev Gondode * , Ankita Garg , Satyajeet Sahoo , Ankit Sharma
Department of Anesthesiology, All India Institute of Medical Sciences, Nagpur, India
Abstract:   (1531 Views)
Coronavirus disease (COVID-19) pandemic has affected worldwide health care. Given the possibility for coronavirus to prompt oxidative stress, masked glucose-6-phosphate dehydrogenase deficiency (G6PD) deficiency in the presence of the COVID-19 viral infection may instigate hemolytic crisis and dangerous consequences in affected individuals. G6PD deficiency is an X-linked recessive disorder that affects some 400 million people worldwide, with a higher prevalence in Africa, the Mediterranean Region, and Asia. A dearth of studies and literature on available antivirals for managing COVID-19 patients with G6PD deficiency brings the healthcare workers to a conundrum. Here, we report an interesting symptomatic case of COVID-19 patient with G6PD deficiency, hypertension, and resolved hepatitis B. Antiviral therapy for COVID-19 positive patients with G6PD deficiency should be individualized by considering the risk and benefit of treatment involved, recommending a multidisciplinary team approach.
Keywords: Coronavirus, G6PD deficiency, Hepatitis B, Remdesivir
Full-Text [PDF 761 kb]   (1691 Downloads)    
Type of Study: Case Report | Subject: Infectious diseases and public health
Received: 2021/06/9 | Accepted: 2021/12/10 | Published: 2021/12/28
References
1. mohfw.gov.in [internet] Ministry of Health and Family Welfare. Government of India. Revised COVID-19 Clinical Management Protocol Algorithm (Adults); c2021. [cited 2021 Nov 02]. Available from: https://www.mohfw.gov.in/
2. Mohanty D, Mukherjee MB, Colah RB. Glucose-6-phosphate dehydrogenase deficiency in India. Indian J Pediatr. 2004; 71 (6): 525-9. [DOI:10.1007/BF02724295]
3. Mukherjee MB, Colah RB, Martin S, Ghosh K. Glucose-6-phosphate dehydrogenase (G6PD) deficiency among tribal populations of India - Country scenario. Indian J Med Res. 2015; 141 (5): 516-20.
4. Peters AL, Van Noorden CJ. Glucose-6-phosphate dehydrogenase deficiency and malaria: cytochemical detection of heterozygous G6PD deficiency in women. J Histochem Cytochem. 2009; 57 (11): 1003-11. [DOI:10.1369/jhc.2009.953828]
5. Takahashi T, Luzum JA, Nicol MR, Jacobson PA. Pharmacogenomics of COVID-19 therapies. NPJ Genom Med. 2020; 5 (1): 1-7. [DOI:10.1038/s41525-020-00143-y]
6. fda.gov [internet]. Food and Drug Administration. FDA Drug Safety Communication: FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems; c2020. [cited 2021 Nov 02]. Available from: https://www.fda.gov/media/137250/download.
7. Beauverd Y, Adam Y, Assouline B, Samii K. COVID‐19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose‐6‐phosphate dehydrogenase deficiency. Eur J Haematol. 2020; 105 (3): 357-9. [DOI:10.1111/ejh.13432]
8. WHO Solidarity Trial Consortium. Repurposed antiviral drugs for Covid-19 interim who solidarity trial results. N Engl J Med. 2021; 384 (6): 497-511. [DOI:10.1056/NEJMoa2023184]
9. RECOVERY Collaborative Group. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020; 383 (21): 2030- 40. [DOI:10.1056/NEJMoa2022926]
10. Rosenstraus M, Chasin LA. Isolation of mammalian cell mutants deficient in glucose-6-phosphate dehydrogenase activity: linkage to hypoxanthine phosphoribosyl transferase. Proceedings of the National Academy of Sciences. 1975; 72 (2): 493-7. [DOI:10.1073/pnas.72.2.493]
11. Pai S, Sprenkle A, Do T, et al. Localization of loci for hypoxanthine phosphoribosyl transferase and glucose-6-phosphate dehydrogenase and biochemical evidence of non-random X chromosome expression from studies of a human X-autosome translocation. Proceedings of the National Academy of Sciences. 1980; 77 (5): 2810- 13. [DOI:10.1073/pnas.77.5.2810]
12. Torequl Islam. Mutation in hprt1 Gene or HPRT Deficiency May be a Restricting Progeny of Favipiravir in Covid-19. Sch Int J Tradit Complement Med. 2020; 3 (8): 162- 4. [DOI:10.36348/sijtcm.2020.v03i08.001]
13. Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot Res. 2020; 73 (9): 593-602. [DOI:10.1038/s41429-020-0336-z]
14. Malek AE, Granwehr BP, Kontoyiannis DP. Doxycycline as a potential partner of COVID-19 therapies. IDCases. 2020; 21: e00864. [DOI:10.1016/j.idcr.2020.e00864]
15. Castro JZ, Fredeking T. Doxycycline modify the cytokine storm in patients with dengue and dengue hemorrhagic fever. Int J Infect Dis. 2010; 14: e44. [DOI:10.1016/j.ijid.2010.02.1586]
16. Bhowmick S, Dang A, Vallish BN, Dang S. Safety and Efficacy of Ivermectin and Doxycycline Monotherapy and in Combination in the Treatment of COVID-19: A Scoping Review. Drug Saf. 2021; 44 (6): .635-44. [DOI:10.1007/s40264-021-01066-y]
17. Aldhaleei WA, Alnuaimi A, Bhagavathula AS. COVID-19 induced hepatitis B virus reactivation: a novel case from the United Arab Emirates. Cureus. 2020; 12 (6): e8645. [DOI:10.7759/cureus.8645]
18. Rodríguez‐Tajes S, Miralpeix A, Costa J, López‐Suñé E, Laguno M, Pocurull A, Lens S, Mariño Z, Forns X. Low risk of hepatitis b reactivation in patients with severe COVID‐19 who receive immunosuppressive therapy. J Viral Hepat. 2021; 28 (1): 89-94. [DOI:10.1111/jvh.13410]
19. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30 (3): 269-71. [DOI:10.1038/s41422-020-0282-0]
20. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020; 383 (19): 1813- 26. [DOI:10.1056/NEJMoa2007764]
21. covid19treatmentguidelines.nih.gov [internet] National Institutes of Health. Covid-19 Treatment Guidelines. Antiviral Drugs That Are Approved or Under Evaluation for the Treatment of COVID-19; c2021. [cited 2021 Nov 02]. Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/.
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.